Venus Remedies inches up on obtaining Marketing Authorizations for range of essential oncology drugs in Ukrain
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Venus Remedies is currently trading at Rs. 334.05, up by 0.30 points or 0.09% from its previous closing of Rs. 333.75 on the BSE.
The scrip opened at Rs. 333.75 and has touched a high and low of Rs. 340.45 and Rs. 332.00 respectively. So far 1266 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 10 has touched a 52 week high of Rs. 429.60 on 05-Jan-2024 and a 52 week low of Rs. 151.15 on 16-Mar-2023.
Last one week high and low of the scrip stood at Rs. 350.15 and Rs. 322.95 respectively. The current market cap of the company is Rs. 447.79 crore.
The promoters holding in the company stood at 41.76%, while Institutions and Non-Institutions held 1.59% and 56.65% respectively.
Venus Remedies has successfully obtained Marketing Authorizations (MAs) for a range of essential oncology drugs in Ukraine (Asia CIS). This includes PACLITAXEL in various strengths of 100mg/16.7mL, 260mg/43.3mL, 300mg/50mL and 30mg/5mL, OXALIPLATIN in concentrations of 50mg/10mL and 100mg/20mL and lRINOTECAN in formulations of 100mg/5mL and 40mg/2mL. These approvals mark significant progress for Venus Remedies in expanding its market presence and providing access to critical medications for cancer patients in the region. The company remains committed to its mission of delivering high quality pharmaceuticals to improve healthcare outcomes globally.
Venus Remedies is one of the handful player in pharmaceutical sector to launch world global injectable manufacturers.
